WallStreetZenWallStreetZen

NASDAQ: PHIO
Phio Pharmaceuticals Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for PHIO

Based on 2 analysts offering 12 month price targets for Phio Pharmaceuticals Corp

Min Forecast
$4.00+84.33%
Avg Forecast
$9.00+314.75%
Max Forecast
$14.00+545.16%

Should I buy or sell PHIO stock?

Based on 2 analysts offering ratings for Phio Pharmaceuticals Corp.

Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although PHIO's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates PHIO as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their PHIO stock forecasts and price targets.

PHIO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-06-25
lockedlocked$00.00+00.00%2025-04-08

1 of 1

Forecast return on equity

Is PHIO forecast to generate an efficient return?

Company
-16.16%
Industry
86.7%
Market
66.57%
PHIO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PHIO forecast to generate an efficient return on assets?

Company
-14.64%
Industry
24.01%
PHIO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PHIO earnings per share forecast

What is PHIO's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$1.58
Avg 2 year Forecast
-$0.83
Avg 3 year Forecast
-$0.41

PHIO revenue forecast

What is PHIO's revenue in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$75.0M

PHIO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PHIO$2.17$9.00+314.75%Buy
PSTV$0.32$10.83+3,285.31%Buy
CSCI$3.34N/AN/A
IMRN$1.85N/AN/A
CBIO$15.90$25.00+57.23%Strong Buy
View Top Biotech Stocks

Phio Pharmaceuticals Stock Forecast FAQ

Is Phio Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: PHIO) stock is to Buy PHIO stock.

Out of 2 analysts, 0 (0%) are recommending PHIO as a Strong Buy, 2 (100%) are recommending PHIO as a Buy, 0 (0%) are recommending PHIO as a Hold, 0 (0%) are recommending PHIO as a Sell, and 0 (0%) are recommending PHIO as a Strong Sell.

If you're new to stock investing, here's how to buy Phio Pharmaceuticals stock.

What is PHIO's earnings growth forecast for 2025-2027?

(NASDAQ: PHIO) Phio Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.19%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.72%.

Phio Pharmaceuticals's earnings in 2025 is -$6,765,000.On average, 1 Wall Street analyst forecast PHIO's earnings for 2025 to be -$7,581,083, with the lowest PHIO earnings forecast at -$7,581,083, and the highest PHIO earnings forecast at -$7,581,083. On average, 1 Wall Street analyst forecast PHIO's earnings for 2026 to be -$3,982,468, with the lowest PHIO earnings forecast at -$3,982,468, and the highest PHIO earnings forecast at -$3,982,468.

In 2027, PHIO is forecast to generate -$1,967,243 in earnings, with the lowest earnings forecast at -$1,967,243 and the highest earnings forecast at -$1,967,243.

What is PHIO's revenue growth forecast for 2025-2025?

(NASDAQ: PHIO) Phio Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 129.99%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10%.

Phio Pharmaceuticals's revenue in 2025 is $0.

In 2025, PHIO is forecast to generate $359,861,550 in revenue, with the lowest revenue forecast at $359,861,550 and the highest revenue forecast at $359,861,550.

What is PHIO's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: PHIO) forecast ROA is -14.64%, which is lower than the forecast US Biotechnology industry average of 24.01%.

What is PHIO's Price Target?

According to 2 Wall Street analysts that have issued a 1 year PHIO price target, the average PHIO price target is $9.00, with the highest PHIO stock price forecast at $14.00 and the lowest PHIO stock price forecast at $4.00.

On average, Wall Street analysts predict that Phio Pharmaceuticals's share price could reach $9.00 by Jun 25, 2026. The average Phio Pharmaceuticals stock price prediction forecasts a potential upside of 314.75% from the current PHIO share price of $2.17.

What is PHIO's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: PHIO) Phio Pharmaceuticals's current Earnings Per Share (EPS) is -$6.42. On average, analysts forecast that PHIO's EPS will be -$1.58 for 2025, with the lowest EPS forecast at -$1.58, and the highest EPS forecast at -$1.58. On average, analysts forecast that PHIO's EPS will be -$0.83 for 2026, with the lowest EPS forecast at -$0.83, and the highest EPS forecast at -$0.83. In 2027, PHIO's EPS is forecast to hit -$0.41 (min: -$0.41, max: -$0.41).

What is PHIO's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: PHIO) forecast ROE is -16.16%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.